戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 rapeutic potential to boost remyelination in demyelinating disorders.
2 vaccination against HSV-1 can help to combat demyelinating disorders.
3 enues for treatment of neurodegenerative and demyelinating disorders.
4 ons, but also provide potential insight into demyelinating disorders.
5 tion contributes to remyelination failure in demyelinating disorders.
6 s may be beneficial in neuroinflammatory and demyelinating disorders.
7 ew strategies for promoting myelin repair in demyelinating disorders.
8  promising new approach for the treatment of demyelinating disorders.
9  new therapeutic avenue for the treatment of demyelinating disorders.
10  a primary goal for regenerative medicine in demyelinating disorders.
11 at promote functional myelin regeneration in demyelinating disorders.
12 ged myelin deteriorates during the course of demyelinating disorders.
13  of benefit for multiple sclerosis and other demyelinating disorders.
14 us system injuries and neurodegenerative and demyelinating disorders.
15  tuberculosis, other serious infections, and demyelinating disorders.
16 XCR2 as a promising drug target for clinical demyelinating disorders.
17 sis and specific gene defects leads to fatal demyelinating disorders.
18 ive Abs in autoimmune central nervous system demyelinating disorders.
19 tractive candidate for therapy of autoimmune demyelinating disorders.
20 ation between HSV-1 infection and multifocal demyelinating disorders.
21 or investigating the MAG to dMAG reaction in demyelinating disorders.
22  its potential as a therapeutic approach for demyelinating disorders.
23  of oligodendrocyte survival in inflammatory demyelinating disorders affecting the CNS.
24 of these central nervous system inflammatory demyelinating disorders and discuss neuropathological st
25  effective remyelination in the treatment of demyelinating disorders and in identifying pathways invo
26 ake it a promising potential therapy for CNS demyelinating disorders and injuries.
27 ce is key to sustaining neurodegeneration in demyelinating disorders and may be considered a potentia
28 r accidents, brain trauma, brain tumors, and demyelinating disorders), and 60 normal controls were ex
29 ated disease (MOGAD) is a recently described demyelinating disorder, and children represent about 50%
30 y develop concurrent or separate episodes of demyelinating disorders, and conversely patients with NM
31 bolic diseases, and traumatic brain injury), demyelinating disorders, and infectious brain lesions.
32   Oligodendrocytes are the primary target of demyelinating disorders, and progressive neurodegenerati
33 ving the lamin B1 gene cause the adult-onset demyelinating disorder, Autosomal Dominant Leukodystroph
34 etaR-Ig as a candidate biological therapy in demyelinating disorders, because it is beneficial during
35 w strategies for therapeutic intervention in demyelinating disorders by promoting oligodendrocyte reg
36 is believed to contribute to immune-mediated demyelinating disorders by targeting the myelin-producin
37 kodystrophy (GLD, Krabbe disease) is a fatal demyelinating disorder caused by a deficiency in the lys
38 multifocal leukoencephalopathy (PML), a rare demyelinating disorder caused by oligodendrocyte destruc
39      We conclude that stathmin expression in demyelinating disorders could have a dual role.
40 e, but after tolerization treatment a lethal demyelinating disorder emerged.
41 egeneration, glial biomarkers for peripheral demyelinating disorders, immunopathogenic biomarkers (su
42 accination against HSV-1 may protect against demyelinating disorders.IMPORTANCE Our work demonstrates
43   Multiple Sclerosis (MS) is an inflammatory demyelinating disorder in which remyelination failure co
44 l myelin damage and are generated in diverse demyelinating disorders in mice and humans, pointing to
45                                              Demyelinating disorders including leukodystrophies are d
46            The evolution of inflammatory and demyelinating disorders, including the degree of recover
47 ance owing to the several dysmyelinating and demyelinating disorders known in humans.
48 e disseminated encephalomyelitis (ADEM) is a demyelinating disorder most common in childhood and adol
49 ic oligodendrocyte loss, which occurs in the demyelinating disorder multiple sclerosis (MS), contribu
50  associated with increased prevalence of the demyelinating disorder multiple sclerosis (MS), suggesti
51 s (EAE), an animal model of the inflammatory demyelinating disorder multiple sclerosis (MS).
52 elitis (EAE) is an animal model of the human demyelinating disorder multiple sclerosis (MS).
53 utes significantly to the development of the demyelinating disorder multiple sclerosis and its animal
54  a deleterious factor in the immune-mediated demyelinating disorder multiple sclerosis.
55 ay a deleterious role in the immune-mediated demyelinating disorder multiple sclerosis.
56 ase or globoid cell leukodystrophy is a rare demyelinating disorder of the central and peripheral ner
57         Multiple sclerosis (MS) is a chronic demyelinating disorder of the central nervous system (CN
58                      Multiple sclerosis is a demyelinating disorder of the central nervous system (CN
59     Multiple sclerosis (MS) is an autoimmune demyelinating disorder of the central nervous system (CN
60 eature of multiple sclerosis (MS), a chronic demyelinating disorder of the central nervous system, fe
61 e sclerosis (MS), an inflammatory autoimmune demyelinating disorder of the central nervous system, is
62 ral form of X-linked adrenoleukodystrophy, a demyelinating disorder of the central nervous system, le
63 tis is considered a monophasic, inflammatory demyelinating disorder of the central nervous system.
64 OG) antibody-associated disease (MOGAD) is a demyelinating disorder of the central nervous system.
65 tis (EAE) is a CD4 Th1-mediated inflammatory demyelinating disorder of the CNS and a well-established
66         Multiple sclerosis (MS) is a chronic demyelinating disorder of the CNS characterized by immun
67          Multiple sclerosis is an autoimmune demyelinating disorder of the CNS, characterized by infl
68   Multiple sclerosis is a chronic autoimmune demyelinating disorder of the CNS.
69   Multiple sclerosis (MS) is an inflammatory demyelinating disorder of the CNS.
70      Neuromyelitis optica is an inflammatory demyelinating disorder of the CNS.
71        Multiple sclerosis is an inflammatory demyelinating disorder of the CNS.
72 ve multifocal leukoencephalopathy (PML) is a demyelinating disorder of the human brain caused by infe
73          Multiple sclerosis is an autoimmune demyelinating disorder of the nervous system that is com
74 , optic neuritis presents as an inflammatory demyelinating disorder of the optic nerve, which can be
75 s include both the vascular and inflammatory demyelinating disorders of adulthood, as well as the chi
76                                              Demyelinating disorders of the central nervous system ar
77                                  Adult-onset demyelinating disorders of the central nervous system re
78 unty population-based cohort of inflammatory demyelinating disorders of the central nervous system we
79 lay a key regulatory role in immune-mediated demyelinating disorders of the central nervous system, i
80  of MOG-Abs and their role in autoimmune and demyelinating disorders of the CNS.
81 ay be a therapeutically tractable target for demyelinating disorders of the CNS.SIGNIFICANCE STATEMEN
82  infections, malignancies, lymphomas, lupus, demyelinating disorders, or deaths were reported.
83 d disease (MOG-AAD) is a recently recognized demyelinating disorder predominantly affecting children
84 ng central nervous system (CNS) inflammatory demyelinating disorders related to NMO from multiple scl
85 ding of disease pathogenesis and recovery in demyelinating disorders remains incomplete.
86 disseminated encephalomyelitis) and from non-demyelinating disorders such as chronic small vessel dis
87 okine associated with the pathophysiology of demyelinating disorders such as multiple sclerosis and v
88 nation.SIGNIFICANCE STATEMENT Myelin loss in demyelinating disorders such as multiple sclerosis resul
89 evelopment of therapies to promote repair in demyelinating disorders such as multiple sclerosis.
90 slowing of conduction velocities in acquired demyelinating disorders, such as chronic inflammatory de
91 herapies to enhance remyelination in chronic demyelinating disorders, such as PMS.
92 /- mice to IFN-gamma implicates ER stress in demyelinating disorders that are induced by CNS inflamma
93          To examine the action(s) of 4-AP in demyelinating disorders, the drug was administered at cl
94 ompensate myelin loss in the early phases of demyelinating disorders, this spontaneous reparative pot
95 nisms sustaining endogenous remyelination in demyelinating disorders, we focused our attention on end
96  imply that the development of therapies for demyelinating disorders will require defining which OPC
97 sorders, and conversely patients with NMO or demyelinating disorders with atypical symptoms (eg, dysk
98 ein, which is defective in patients with the demyelinating disorder X-linked ALD.